Intellia Therapeutics, Inc. (NTLA) vs Stoke Therapeutics, Inc. (STOK)
- Intellia Therapeutics, Inc. NTLA 11.42 +0.71%
- Stoke Therapeutics, Inc. STOK 24.17 −1.79%
Intellia Therapeutics, Inc. and Stoke Therapeutics, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Stoke Therapeutics, Inc. are of similar size ($1.6B and $1.6B). Intellia Therapeutics, Inc. grew revenue faster over the last twelve months: 12.6% against −86.2%. Intellia Therapeutics, Inc. has the higher net margin (−672.2% vs −753.6%) and the higher return on invested capital (−91.3% vs −264.8%). Across the 15 metrics below, Intellia Therapeutics, Inc. leads on 11 and Stoke Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | NTLA | STOK | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (711.66%) | (809.69%) | 0.00% |
| Net margin | (672.16%) | (753.60%) | 0.00% |
| Free cash flow margin | (585.82%) | (654.92%) | 0.00% |
| Return on equity | (55.44%) | (61.10%) | (56.36%) |
| Return on assets | (45.55%) | (53.41%) | (48.04%) |
| Return on invested capital | (91.28%) | (264.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack